414P - Characteristics, incidence, and survival of primary cerebral lymphoma: A population based study

Abstract

BackgroundPrimary cerebral lymphoma (PCL) is a rare malignancy representing less than 1.5% of brain tumors. Given the lack of studies in the literature that describe PCL, we used data from the Surveillance, Epidemiology, and End Results (SEER) database to investigate PCL’s prognostic factors, incidence and survival rates. MethodsWe conducted a retrospective population-based cohort study using SEER database from 1983-2014. Patients with primary lymphoma as their only primary malignancy analyzed. Patients who were diagnosed by autopsy, had no active follow up in the registry and with unknown Ann Arbor Staging, or radiology status were excluded. We also calculated the frequencies and the average annual age-adjusted rate (AAR) of PCL patients between 2000 and 2015. Uni- and multivariable accelerated failure time regression were used to identify possible prognostic factors affecting the patient’s survival. ResultsWe identified 1,196 PCL cases, with an average age of diagnosis 56.71±17.28 years and 59.9% were males. Diffuse B-cell lymphoma was the most prevalent sub-type (61.3%). AAR was 0.14 per 100,000. These rates were higher in males, Asian or Pacific Islander and increasing with age. PCL-specific 1-year, 2-year, and 5-year survival rates were 89.6%, 84.4%, and 67%, respectively. Increased age (HR: 1.02, 95%CI=1.01–1.03, P<0.001) and recent diagnosis after 2002 (HR: 2.42, CI=1.46–3.42, P<0.001) were significantly associated with shorter survival, while having a PCL in the temporal lobe (HR: 0.62, 95%CI=0.40–0.98, P=0.040), or parietal lobe (HR: 0.63, 95%CI=0.42–0.94, P=0.024) as compared to the other sites, and receiving radiation (HR: 0.37, 95% CI=0.15–0.92, P=0.033) or chemotherapy (HR: 0.64, 95%CI=0.50–0.83, P=0.001) were associated with improved survival. ConclusionsThis is the first report to shed light on PCL’s incidence, survival rate, and prognostic factors. As a result, it will provide physicians and researchers with insights about this rare malignancy. Legal entity responsible for the studySherief Ghozy. FundingHas not received any funding. DisclosureAll authors have declared no conflicts of interest.